X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
Details:
COPIKTRA (duvelisib) is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first US approved dual inhibitor of PI3K-delta and PI3K-gamma, two enzymes known to help support the growth and survival of malignant cells.
Lead Product(s): Duvelisib
Therapeutic Area: Oncology Product Name: Copiktra
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
COPIKTRA is an oral dual inhibitor of the PI3K-delta and gamma pathways, which are involved in the proliferation, growth, and migration of malignant cells and are thought to play a role in the formation and maintenance of a supportive tumor microenvironment.
Lead Product(s): Duvelisib
Therapeutic Area: Oncology Product Name: Copiktra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2021
Details:
Verastem’s sale of COPIKTRA to Secura Bio follows Verastem’s previously announced new strategic direction focused on development of its RAF/MEK inhibitor (VS-6766) and FAK inhibitor (defactinib) program in KRAS mutant (KRASmt) solid tumors.
Lead Product(s): Duvelisib
Therapeutic Area: Oncology Product Name: Copiktra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Secura Bio
Deal Size: $381.0 million Upfront Cash: $70.0 million
Deal Type: Divestment September 30, 2020
Details:
Verastem’s sale of COPIKTRA follows the Company’s previously announced strategic direction to focus on maximizing the broad potential of its RAF/MEK inhibitor (VS-6766) and FAK inhibitor (defactinib) program in KRAS mutant (KRASmt) solid tumors.
Lead Product(s): Duvelisib
Therapeutic Area: Oncology Product Name: Copiktra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Secura Bio
Deal Size: $381.0 million Upfront Cash: $70.0 million
Deal Type: Divestment August 10, 2020
Details:
The collaboration aims to define predictors of response to PI3 kinase inhibition in relapsed/refractory T-cell lymphomas.
Lead Product(s): Duvelisib
Therapeutic Area: Oncology Product Name: Copiktra
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Weinstock Laboratory
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 04, 2020
Details:
CSPC’s study is designed to evaluate the antitumor activity and safety of duvelisib administered to patients diagnosed with relapsed or refractory follicular lymphoma.
Lead Product(s): Duvelisib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
